Monocyte recruitment and macrophage proliferation in atherosclerosis

Kardiologia Polska

Volumn 72, Issue 4, 2014, Pages 311-314

  Swirski, Filip K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BROXURIDINE; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CX3CR1; LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; SCAVENGER RECEPTOR A; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 4;

ADOPTIVE TRANSFER; APOPTOSIS; ATHEROSCLEROSIS; BLOOD; BONE MARROW; CELL DIFFERENTIATION; CELL INFILTRATION; CELL PROLIFERATION; HEMATOPOIESIS; HUMAN; MACROPHAGE; MONOCYTE; NONHUMAN; PARABIOSIS; REVIEW; SIGNAL TRANSDUCTION; SPLEEN; TURNOVER TIME; PATHOPHYSIOLOGY; PHYSIOLOGY;

ATHEROSCLEROSIS; CELL PROLIFERATION; HUMANS; MACROPHAGES; MONOCYTES;

EID: 84933039957     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: 10.5603/KP.a2014.0021     Document Type: Review

References (52)

1. Stary HC. Atlas of atherosclerosis: progression and regression. The encyclopedia of visual medicine series, Parthenon, New York, 1999; 131.
2. Bloom DE, Cafiero ET, Jane-Llopis E et al. The global economic burden of noncommunicable diseases. World Economic Forum, Geneva, 2011.
3. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol, 2006; 6: 508-519.
4. Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science, 2013; 339: 161-166.
5. Hilgendorf I, Swirski FK. Making a difference: monocyte heterogeneity in cardiovascular disease. Curr Atheroscler Rep, 2012; 14: 450-459.
6. Coller BS. Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene? Arterioscler Thromb Vasc Biol, 2005; 25: 658-670.
7. Boring L, Gosling J, Cleary M et al. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature, 1998; 394: 894-897.
8. Combadiere C, Potteaux S, Rodero M et al. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation, 2008; 117: 1649-1657.
9. Gerszten RE, Garcia-Zepeda EA, Lim YC et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature, 1999; 398: 718-723.
10. Gu L, Okada Y, Clinton SK et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell, 1998; 2: 275-281.
11. Kim CJ, Khoo JC, Gillotte-Taylor K et al. Polymerase chain reaction- based method for quantifying recruitment of monocytes to mouse atherosclerotic lesions in vivo: enhancement by tumor necrosis factor-alpha and interleukin-1 beta. Arterioscler Thromb Vasc Biol, 2000; 20: 1976-1982.
12. Lessner SM, Prado HL, Waller EK et al. Atherosclerotic lesions grow through recruitment and proliferation of circulating monocytes in a murine model. Am J Pathol, 2002; 160: 2145-2155.
13. Rajavashisth T, Qiao JH, Tripathi S et al. Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor- deficient mice. J Clin Invest, 1998; 101: 2702-2710.
14. Saederup N, Chan L, Lira SA et al. Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/- mice: evidence for independent chemokine functions in atherogenesis. Circulation, 2008; 117: 1642-1648.
15. Smith JD, Trogan E, Ginsberg M et al. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA, 1995; 92: 8264-8268.
16. Swirski FK, Libby P, Aikawa E et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest, 2007; 117: 195-205.
17. Tacke F, Alvarez D, Kaplan TJ et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest, 2007; 117: 185-194.
18. Robbins CS, Chudnovskiy A, Rauch PJ et al. Extramedullary hematopoiesis generates Ly-6C(high) monocytes that infiltrate atherosclerotic lesions. Circulation, 2012; 125: 364-374.
19. Swirski FK, Pittet MJ, Kircher MF et al. Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc Natl Acad Sci USA, 2006; 103: 10340-10345.
20. Ye D, Zhao Y, Hildebrand RB et al. The dynamics of macrophage infiltration into the arterial wall during atherosclerotic lesion development in low-density lipoprotein receptor knockout mice. Am J Pathol, 2011; 178: 413-422.
21. Aiello RJ, Perry BD, Bourassa PA et al. CCR2 receptor blockade alters blood monocyte subpopulations but does not affect atherosclerotic lesions in apoE(-/-) mice. Atherosclerosis, 2010; 208: 370-375.
22. Calin MV, Manduteanu I, Dragomir E et al. Effect of depletion of monocytes/macrophages on early aortic valve lesion in experimental hyperlipidemia. Cell Tissue Res, 2009; 336: 237-248.
23. Guo J, de Waard V, Van Eck M et al. Repopulation of apolipoprotein E knockout mice with CCR2-deficient bone marrow progenitor cells does not inhibit ongoing atherosclerotic lesion development. Arterioscler Thromb Vasc Biol, 2005; 25: 1014-1019.
24. Stoneman V, Braganza D, Figg N et al. Monocyte/macrophage suppression in CD11b diphtheria toxin receptor transgenic mice differentially affects atherogenesis and established plaques. Circ Res, 2007; 100: 884-893.
25. Schulz C, Gomez Perdiguero E, Chorro L et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science, 2012; 336: 86-90.
26. Jenkins SJ, Ruckerl D, Cook PC et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science, 2011; 332: 1284-1288.
27. Psaltis PJ, Harbuzariu A, Delacroix S et al. Identification of a monocyte- predisposed hierarchy of hematopoietic progenitor cells in the adventitia of postnatal murine aorta. Circulation, 2012; 125: 592-603.
28. Aikawa M, Rabkin E, Sugiyama S et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation, 2001; 103: 276-283.
29. Gordon D, Reidy MA, Benditt EP et al. Cell proliferation in human coronary arteries. Proc Natl Acad Sci USA, 1990; 87: 4600-4604.
30. Katsuda S, Coltrera MD, Ross R et al. Human atherosclerosis. IV. Immunocytochemical analysis of cell activation and proliferation in lesions of young adults. Am J Pathol, 1993; 142: 1787-1793.
31. Lutgens E, Daemen M, Kockx M et al. Atherosclerosis in APOE*3-Leiden transgenic mice: from proliferative to atheromatous stage. Circulation, 1999; 99: 276-283.
32. Lutgens E, de Muinck ED, Kitslaar PJ et al. Biphasic pattern of cell turnover characterizes the progression from fatty streaks to ruptured human atherosclerotic plaques. Cardiovasc Res, 1999; 41: 473-479.
33. Rekhter MD, Gordon D. Active proliferation of different cell types, including lymphocytes, in human atherosclerotic plaques. Am J Pathol, 1995; 147: 668-677.
34. Rosenfeld ME, Ross R. Macrophage and smooth muscle cell proliferation in atherosclerotic lesions of WHHL and comparably hypercholesterolemic fat-fed rabbits. Arteriosclerosis, 1990; 10: 680-687.
35. Hamilton JA, Myers D, Jessup W et al. Oxidized LDL can induce macrophage survival, DNA synthesis, and enhanced proliferative response to CSF-1 and GM-CSF. Arterioscler Thromb Vasc Biol, 1999; 19: 98-105.
36. Martens JS, Reiner NE, Herrera-Velit P et al. Phosphatidylinositol 3-kinase is involved in the induction of macrophage growth by oxidized low density lipoprotein. J Biol Chem, 1998; 273: 4915-4920.
37. Hamilton JA, Jessup W, Brown AJ et al. Enhancement of macrophage survival and DNA synthesis by oxidized-low-density-lipoprotein (LDL)-derived lipids and by aggregates of lightly oxidized LDL. Biochem J, 2001; 355: 207-214.
38. Robbins CS, Hilgendorf I, Weber GF et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med, 2013; 19: 1166-1172.
39. Parks BW, Lusis AJ. Macrophage accumulation in atherosclerosis. N Engl J Med, 2013; 369: 2352-2353.
40. Randolph GJ. Proliferating macrophages prevail in atherosclerosis. Nat Med, 2013; 19:1094-1095.
41. Dutta P, Courties G, Wei Y et al. Myocardial infarction accelerates atherosclerosis. Nature, 2012; 487: 325-329.
42. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol, 2008; 8: 958-969.
43. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest, 2012; 122: 787-795.
44. Mantovani A, Garlanda C, Locati M. Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler Thromb Vasc Biol, 2009; 29: 1419-1423.
45. Moore KJ, Freeman MW. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol, 2006; 26: 1702-1711.
46. Hazen SL. Oxidized phospholipids as endogenous pattern recognition ligands in innate immunity. J Biol Chem, 2008; 283: 15527-15531.
47. Kunjathoor VV, Febbraio M, Podrez EA et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem, 2002; 277: 49982-49988.
48. Sakai M, Miyazaki A, Hakamata H et al. The scavenger receptor serves as a route for internalization of lysophosphatidylcholine in oxidized low density lipoprotein-induced macrophage proliferation. J Biol Chem, 1996; 271: 27346-27352.
49. Seimon TA, Obstfeld A, Moore KJ et al. Combinatorial pattern recognition receptor signaling alters the balance of life and death in macrophages. Proc Natl Acad Sci USA, 2006; 103: 19794-19799.
50. Manning-Tobin JJ, Moore KJ, Seimon TA et al. Loss of SR-A and CD36 activity reduces atherosclerotic lesion complexity without abrogating foam cell formation in hyperlipidemic mice. Arterioscler Thromb Vasc Biol, 2009; 29: 19-26.
51. Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature, 2008; 451: 904-913.
52. Tabas I, Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science, 2013; 339: 166-172.